1. R. Jayaraman. Antibiotic resistance: an
overview of mechanisms and a paradigm
shift. Current Science. 2009; Vol. 96: No.11:
1475-1484.
2. Raul Isturiz., Global resistance trends and
the potential impact on empirical therapy.
International Journal of Antimicrobial
Agents. 2008; 32: S4 S201-S206.
3. Bratu S, Mooty M, Nichani S, et al.
Emergence of KPC-possessing Klebsiella
pneumoniae in Brooklyn, New York:
epidemiology and recommendations for
detection. Antimicrobial Agents and
Chemotherapy. 2005; 49: 3018-3020.
4. Nordmann P, Poirel L. Emerging
carbapenemases in Gram negative aerobes.
Clin Microbiol Infect. 2002; 8: 321-331.
5. Carson C, Naber KG. Role of
fluoroquinolones in the treatment of
serious bacterial urinary tract infections.
Drugs. 2004; 64: 1359-1373.
6. National Nosocomial Infections
Surveillance (NNIS) System Report, data
summary from January 1992 through June
2004, issued October 2004. Am J Infect
Control. 2004; 32: 470-485
7. Kazuhiko Yoneda , Hiroki Chikumi ,
Takeshi Murata b, Naomasa Gotoh, Hiroyuki
Yamamoto, Hiromitsu Fujiwara, Takeshi
Nishino, Eiji Shimizu. Measurement of
Pseudomonas aeruginosa multidrug efflux
pumps by quantitative real-time
polymerase chain reaction. FEMS
Microbiology Letters. 2005; 243: 125-131.
8. F.Van Bambeke, Y. Glupczynski, P.
Plesiat, J. C. Pechere and P. M. Tulkens.
Antibiotic efflux pumps in prokaryotic cells:
occurrence, impact on resistance and
strategies for the future of antimicrobial
therapy. Journal of Antimicrobial
Chemotherapy. 2003; 51: 1055-1065.
9. Lomovskaya, O.; Lee, A.; Hoshino, K.;
Ishida, H.; Mistry, A.;Warren, M.S.; Boyer,
E.; Chamberland, S. and Lee, V.J. Use of a
Genetic Approach To Evaluate the
Consequences of Inhibition of Efflux Pumps
in Pseudomonas aeruginosa. Antimicrobial
Agents Chemotherapy. 1999; 43(6): 1340-
1346.
10. Performance Standards for
Antimicrobial Disk Susceptibility Tests;
Research Article CODEN: IJPRNK ISSN: 2277-8713
C. R. Surendranath, IJPRBS, 2013; Volume 2(5):170-176 IJPRBS
Available Online at www.ijprbs.com
175
Approved Standard.Ninth Edition. Clinical
and Laboratory Standard Institute
Document. Clinical and Laboratory
Standards Institute. Wayne, Pennsylvania.
M2-A9. 2006.
11. Matthew E. Falagas, Sofia Marakid,
Drosos E. Karageorgopoulosa, Antonia C.
Kastoris,Emmanuel Mavromanolakis,
George Samonis. Antimicrobial
susceptibility of multidrug-resistant (MDR)
and extensively drug-resistant (XDR)
Enterobacteriaceae isolates to fosfomycin.
International Journal of Antimicrobial
Agents. 2010; 35: 240-243.
12. Methods for dilution antimicrobial
susceptibility tests for bacteria that grow
aerobically; Approved standard. Seventh
edition. Clinical and Laboratory Standard
Institute Document. Clinical and Laboratory
Standards Institute. Wayne, Pennsylvania.
M7-A7. 2006.
13. Anja Schumacher, Petra Steinke, Ju rgen
A. Bohnert, Murat Akova, Daniel Jonas and
Winfried V. Kern. Effect of 1-(1-
naphthylmethyl)-piperazine, a novel
putative efflux pump inhibitor, on
antimicrobial drug susceptibility in clinical
isolates of Enterobacteriaceae other than
Escherichia coli. Journal of Antimicrobial
Chemotherapy. 2006; 57: 344-348.
14. Omoregie, R., Airueghionmon,
D.J.U.,Okonkwo, J.O., Airueghionmon, U.E.,
Ibeh, I.N. and Ogefere, H.O. Prevalence of
multidrug efflux pump requiring
ciprofloxacin, ofloxacin and pefloxacin as
substrates, among clinical isolates of
Pseudomonas aeruginosa. Malaysian
Journal of Microbiology. 2007; Vol 3(2): 37-
40.
15. Joaquim Ruiz, Anna Ribera, Angels
Jurado, Francesc Marco and Jordi Vila.
Evidence for a reserpine-affected
mechanism of resistance to tetracycline in
Neisseria gonorrhoeae. APMIS. 2005; 113:
670-674.
16. Olga Lomovskaya, Mark S. Warren,
Angela Lee, Jorge Galazzo, Richard Fronko,
May Lee, Johanne Blais, Deidre Cho,
Suzanne Chamberland, Tom Renau, Roger
Leger, Scott Hecker, Will Watkins, Kazuki
Hoshino, Hiroko Ishida, And Ving J. Lee.
Identification and characterization of
inhibitors of multidrug resistance efflux
pumps in Pseudomonas aeruginosa: Novel
agents for combination therapy.
Antimicrobial Agents and Chemotherapy.
2001; 45: 105-116.
17. Laurent Mamelli, Jean-Pierre Amoros,
Jean-Marie Pages, Jean-Michel Bolla. A
phenylalanine-arginine β-naphthylamide
sensitive multidrug efflux pump involved in
intrinsic and acquired resistance of
Campylobacter to macrolides. International
Journal of Antimicrobial Agents. 2003; 22:
237-241.
18. Abolghasem Tohidpour , Shahin Najar
Peerayeh,Jalil F. Mehrabadi , Hadi Rezaei
Yazdi, Determination of the Efflux Pump-
Mediated Resistance Prevalence in
Pseudomonas aeruginosa, Using an Efflux
Research Article CODEN: IJPRNK ISSN: 2277-8713
C. R. Surendranath, IJPRBS, 2013; Volume 2(5):170-176 IJPRBS
Available Online at www.ijprbs.com
176
Pump Inhibitor. Curr Microbiol. 2009; 59:
352-355.
19. Zgurskaya HI, Nikaido H. Multidrug
resistance mechanisms: drug efflux across
two membranes. Mol Microbiol. 2000;
37(2): 219-25.
20. Abdallah Mahamoud, Jacqueline
Chevalier, Sandrine Alibert-Franco, Winfried
V. Kern and Jean-Marie Pages. Antibiotic
efflux pumps in Gram-negative bacteria: the
inhibitor response strategy. Journal of
Antimicrobial Chemotherapy.2007;
Volume59; 6: 223-1229.
21. Mark I. Garvey and Laura J. V. Piddock.
The efflux pump inhibitor reserpine selects
Multidrug-Resistant Streptococcus
pneumoniae Strains that overexpress the
ABC transporters PatA and PatB.
Antimicrobial Agents and Chemotherapy.
2008; 1677–1685.
22. Denice C. Bay, Kenton L. Rommens,
Raymond J. Turner. Small multidrug
resistance proteins: A multidrug transporter
family that continues to grow. Biochimica et
Biophysica Acta. 2008; 1778: 1814-1838.
23. Lin-Li Chang, Hui-Feng Chen, Chung-Yu
Chang, Tsong-Ming Lee and Wen-Jeng Wu.
Contribution of integrons, and SmeABC and
SmeDEF efflux pumps to multidrug
resistance in clinical isolates of
Stenotrophomonas maltophilia. Journal of
Antimicrobial Chemotherapy. 2004; 53:
518-521.
24. Lomovskaya, O., and W. Watkins.
Inhibition of efflux pumps as a novel
approach to combat drug resistance in
bacteria. J. Mol. Microbiol. Biotechnol.
2001; 3: 225-236.
25. Keith Poole. Efflux-Mediated Resistance
to Fluoroquinolones in Gram-Negative
Bacteria. Antimicrobial Agents and
Chemotherapy. 2000; 2233-2241.
26. Li, X.Z., and Nikaido, H. Efflux-mediated
drug resistance in bacteria. Drugs. 2004; 64:
159-204.
27. Ayush Kumar, Herbert P. Schweizer.
Bacterial resistance to antibiotics: Active
efflux and reduced uptake. Advanced Drug
Delivery Reviews. 2005; 1486-1513.
28. K. Poole. Efflux-mediated
multiresistance in Gram-negative bacteria.
Clin Microbiol Infect. 2004; 10: 12-26.
29. Mathew D. Routh , Chih-Chia Su , Qijing
Zhang , Edward W. Yu. Structures of AcrR
and CmeR: Insight into the mechanisms of
transcriptional repression and multi-drug
recognition in the TetR family of regulators.
Biochimica et Biophysica Acta . 2009; 1794:
844-851.
30. H. Wang, J.L. Dzink-Fox, M. Chen, S.B.
Levy, Genetic characterization of highly
fluoroquinolone-resistant clinical
Escherichia coli strains from China: role of
acrR mutations. Antimicrobial Agents and
Chemotherapy. 2001; 45: 1515-1521.
Thank you for copying data from http://www.arastirmax.com
